HighTower Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

HighTower Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$873K	Buy	27,773 +1,440	+5%	+$42.5K	﹤0.01%	2329
2026 Q1	$652K	Buy	26,333 +2,489	+10%	+$59.3K	﹤0.01%	2498
2025 Q4	$557K	Buy	23,844 +9,238	+63%	+$206K	﹤0.01%	2527
2025 Q3	$288K	Buy	+14,606	New	+$300K	﹤0.01%	3081
2025 Q2	–	Sell	-81,340	Closed	-$1.97M	–	3794
2025 Q1	$1.97M	Buy	+81,340	New	+$1.83M	﹤0.01%	1532
2021 Q3	–	Sell	-22,751	Closed	-$132K	–	3227
2021 Q2	$132K	Buy	+22,751	New	+$117K	﹤0.01%	2752
2020 Q3	–	Sell	-11,042	Closed	-$50K	–	2570
2020 Q2	$50K	Hold	11,042	–	–	﹤0.01%	2197
2020 Q1	$43K	Buy	11,042 +131	+1%	+$538	﹤0.01%	2023
2019 Q4	$42K	Buy	10,911 +500	+5%	+$2.34K	﹤0.01%	2132
2019 Q3	$56K	Buy	+10,411	New	+$55.5K	﹤0.01%	2213
2018 Q4	–	Sell	-12,411	Closed	-$47K	–	2229
2018 Q3	$47K	Hold	12,411	–	–	﹤0.01%	2127
2018 Q2	$38K	Buy	12,411 +1,000	+9%	+$3.03K	﹤0.01%	2081
2018 Q1	$28K	Buy	11,411 +1,000	+10%	+$3.32K	﹤0.01%	2052
2017 Q4	$41K	Buy	+10,411	New	+$34.4K	﹤0.01%	2117

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HighTower Advisors's CPRX Position: Q2 2026 in Review

HighTower Advisors increased its Catalyst Pharmaceutical (CPRX) stake by 5.5% in Q2 2026, buying an estimated $42.5K and bringing the position to 27,773 shares worth $873K. The position accounts for ﹤0.01% of the portfolio, ranked #2329.

HighTower Advisors first reported a position in CPRX in Q4 2017 and has held it in 14 quarters since. The position peaked at $1.97M in Q1 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

HighTower Advisors held 27,773 shares of Catalyst Pharmaceutical worth $873K as of Q2 2026.
HighTower Advisors bought 1,440 Catalyst Pharmaceutical shares in Q2 2026, an estimated $42.5K.
Catalyst Pharmaceutical made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2329 holding.
HighTower Advisors first reported a position in Catalyst Pharmaceutical in Q4 2017 and has held it in 14 quarters since.
HighTower Advisors's Catalyst Pharmaceutical position peaked at $1.97M in Q1 2025.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.